Carmell Therapeutics
Pittsburgh, US · Delaware corporation · 1 known investors
Find your way into Carmell Therapeutics
Founders & leadership
AI
Alan I. WestExecutive
PK
Paul KornblithExecutive
Board
WN
William NewlinBoard director
JJ
James JordanBoard director
RU
Richard UptonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$13.2M disclosed across 10 rounds · 2013–2020
▶$2.4MraisedSep 2020 · 37 investors · BiotechnologyRule 506(b)
▶$2.4MraisedSep 2020 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James HartExecutive Officer
- David W. AndersonDirector
- Donna GodwardExecutive Officer
- Stephanie KladakisExecutive Officer
- Richard UptonDirector
- Wendy DiCiccoDirector
- Randolph HubbellExecutive Officer, Director
- Offering amount
- $3.5M
- Amount sold
- $2.4M
- Sales commissions
- $37K
- Placement agents
- Alere Financial Partners
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$50KraisedJul 2020 · 1 investors · BiotechnologyRule 506(b)
▶$50KraisedJul 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randolph HubbellExecutive Officer, Director
- Richard UptonDirector
- Wendy DiCiccoDirector
- Stephanie KladakisExecutive Officer
- David W. AndersonDirector
- Offering amount
- $50K
- Amount sold
- $50K
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.2MraisedMar 2019 · 44 investors · BiotechnologyRule 506(b)
▶$5.2MraisedMar 2019 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David W. AndersonDirector
- Wendy DiCiccoDirector
- James HartExecutive Officer
- James F. JordanDirector
- Randolph HubbellExecutive Officer, Director
- Stephanie KladakisExecutive Officer
- Richard UptonDirector
- Donna GodwardExecutive Officer
- Offering amount
- $7.5M
- Amount sold
- $5.2M
- Sales commissions
- $855K
- Placement agents
- Dalmore Group, LLC
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$439.2KraisedApr 2018 · 6 investors · BiotechnologyRule 506(b)
▶$439.2KraisedApr 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephanie KladakisExecutive Officer
- James F. JordanDirector
- James HartExecutive Officer
- Richard UptonDirector
- David W. AndersonDirector
- Randolph HubbellExecutive Officer, Director
- Donna GodwardExecutive Officer
- Offering amount
- $6M
- Amount sold
- $439.2K
- Minimum investment
- $25K
- Sales commissions
- $500K
- Placement agents
- Dalmore Group, LLC
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedDec 2017 · 25 investors · BiotechnologyRule 506(b)
▶$2MraisedDec 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Donna GodwardExecutive Officer
- James F. JordanDirector
- Richard UptonDirector
- Randolph HubbellExecutive Officer, Director
- Stephanie KladakisExecutive Officer
- James HartExecutive Officer
- David W. AndersonDirector
- Offering amount
- $2M
- Amount sold
- $2M
- Minimum investment
- $3.7K
- First sale
- Sep 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.1MraisedApr 2017 · 25 investors · BiotechnologyRule 506(b)
▶$1.1MraisedApr 2017 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard UptonDirector
- David W. AndersonDirector
- Randolph HubbellExecutive Officer, Director
- James HartExecutive Officer
- Donna GodwardExecutive Officer
- Stephanie KladakisExecutive Officer
- James F. JordanDirector
- Offering amount
- $2M
- Amount sold
- $1.1M
- Minimum investment
- $10K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$774.9KraisedFeb 2016 · 8 investors · BiotechnologyRule 506(b)
▶$774.9KraisedFeb 2016 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan I. WestExecutive Officer, Director
- Paul KornblithExecutive Officer, Director
- William NewlinExecutive Officer, Director
- James JordanDirector
- Richard UptonDirector
- Offering amount
- $1M
- Amount sold
- $774.9K
- Minimum investment
- $5.7K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$137.2KraisedAug 2015 · 5 investors · BiotechnologyRule 506(b)
▶$137.2KraisedAug 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alan I. WestExecutive Officer, Director
- James JordanDirector
- Paul KornblithExecutive Officer, Director
- Richard UptonDirector
- William NewlinDirector
- Offering amount
- $300K
- Amount sold
- $137.2K
- First sale
- Jul 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Carmell Therapeutics's investors?
- Carmell Therapeutics's investors include CANTILEVER INVESTORS.
- How much funding has Carmell Therapeutics raised?
- Carmell Therapeutics has disclosed $13.2M raised across 10 rounds.
- Where is Carmell Therapeutics headquartered?
- Carmell Therapeutics is headquartered in Pittsburgh, US.